Making treatment decisions is a tough choice for oncologists: a therapy might save or significantly extend one patient’s life but not deliver the desired outcome for another patient.
COVID-19 drugs, vaccines and diagnostics that are developed and tested within new international guidelines can expect rapid assessment and authorisation.
